<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03138421</url>
  </required_header>
  <id_info>
    <org_study_id>ABX-1431_PN009</org_study_id>
    <nct_id>NCT03138421</nct_id>
  </id_info>
  <brief_title>Central Pain Study for ABX-1431</brief_title>
  <official_title>A Double-Blind, Placebo-Controlled, Crossover Study to Evaluate the Safety and Efficacy of ABX-1431 in Patients With Central Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abide Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abide Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will determine the safety and tolerability of ABX-1431 in patients with central&#xD;
      pain when added on to background pain therapy.&#xD;
&#xD;
      During the course of this study, each participant will take a daily dose of 20 mg of ABX-1431&#xD;
      or a matching placebo for approximately 7 to 9 weeks.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a double-blind, placebo-controlled crossover study, randomized, crossover study of&#xD;
      ABX-1431 HCl as add-on therapy in the treatment of central neuropathic pain.The efficacy of&#xD;
      ABX-1431 will also be assessed by the change in pain intensity scores using a numerical&#xD;
      rating scale (NRS-11).&#xD;
&#xD;
      All patients will undergo a screening visit for enrollment criteria. Eligible patients will&#xD;
      be treated with daily medication for 7 to 9 weeks, which will include some treatment with&#xD;
      placebo and some treatment with ABX-1431 HCl. Patients will use a web based application to&#xD;
      record their daily average pain using a numerical rating scale (NRS-11).&#xD;
&#xD;
      This study will enroll up to 32 patients with chronic central pain due to one of the four&#xD;
      following diagnostic groups: Neuromyeliltis Optica Spectrum Disorder (NMOSD), longitudinally&#xD;
      extensive transverse myelitis (LETM), Multiple Sclerosis (MS), and Transverse Myelitis (TM).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 1, 2017</start_date>
  <completion_date type="Actual">July 24, 2018</completion_date>
  <primary_completion_date type="Actual">July 23, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in mean pain score between ABX-1431 HCl and placebo based on the Pain NRS-11 ordinal numeric rating scale</measure>
    <time_frame>placebo, treatment (14 days)</time_frame>
    <description>The treatment difference of ABX-1431 HCl versus placebo is estimated from the change from baseline in daily NRS-11 Pain to the final 7 days of treatment in each two-week treatment period. Baseline levels of pain or taken from the final 7 days of treatment in the period preceding each double-blind treatment period.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Short Form Brief Pain Inventory (SF-BPI) Scores</measure>
    <time_frame>placebo, treatment (14 days)</time_frame>
    <description>Difference in the change from baseline between ABX-1431 HCl and placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short-Form McGill Pain Questionnaire-2 (SF-MPQ-2)</measure>
    <time_frame>placebo, treatment (14 days)</time_frame>
    <description>Difference in the change from baseline between ABX-1431 HCl and placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Global Impression of Change (PGIC) score</measure>
    <time_frame>placebo, treatment (14 days)</time_frame>
    <description>Difference in the change from baseline between ABX-1431 HCl and placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients achieving and maintaining &gt;30%, &gt;50%, reduction in mean pain intensity score compared to baseline and cumulative proportion of responders' analysis</measure>
    <time_frame>placebo, treatment (14 days)</time_frame>
    <description>Difference in the change from baseline between ABX-1431 HCl and placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Actigraphically estimated parameters of sleep (WASO, TST, sleep efficiency, average overnight activity counts) and general activity measured by percentage of sedentary time, and moderate to high intensity activity</measure>
    <time_frame>placebo, treatment (14 days)</time_frame>
    <description>Difference in the change from baseline between ABX-1431 HCl and placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleep interference (NRS-11) A NRS-11 scale recording sleep interference due to transverse myelitis pain / central pain in the previous week (in which 0 = no interference and 10 = greatest possible interference)</measure>
    <time_frame>placebo, treatment (14 days)</time_frame>
    <description>Difference in the change from baseline between ABX-1431 HCl and placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ABX-11431 and metabolite M55 plasma PK</measure>
    <time_frame>placebo, treatment (14 days)</time_frame>
    <description>Difference in the change from baseline between ABX-1431 HCl and placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2-AG hydrolysis in PBMC</measure>
    <time_frame>placebo, treatment (14 days)</time_frame>
    <description>Difference in the change from baseline between ABX-1431 HCl and placebo</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Neuromyelitis Optica Spectrum Disorder</condition>
  <condition>Transverse Myelitis</condition>
  <condition>Multiple Sclerosis</condition>
  <condition>Longitudinally Extensive Transverse Myelitis</condition>
  <arm_group>
    <arm_group_label>ABX-1431 HCl</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABX-1431 HCl</intervention_name>
    <description>ABX-1431 HCl, capsules, 20 mg</description>
    <arm_group_label>ABX-1431 HCl</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with chronic central pain, present for at least 3 months due to one of the&#xD;
             four following diagnostic groups: NMOSD, LETM, MS, or TM.&#xD;
&#xD;
               -  Patient has a diagnosis of NMOSD with anti-AQP4 IgG or without AQP4-IgG as&#xD;
                  defined by the International Panel for NMO Diagnosis at least 3 months prior to&#xD;
                  the screening visit (IPND 2015)&#xD;
&#xD;
               -  Patients with idiopathic, LETM, comprising an intramedullary MRI lesion or&#xD;
                  continuous segments of spinal cord atrophy with a clinical history consistent&#xD;
                  with acute myelitis, and with chronic pain syndrome consistent with the lesion&#xD;
                  neuroanatomy may be enrolled. These LETM patients must also demonstrate evidence&#xD;
                  of acute, inflammatory myelopathy in the past (e.g. clinically acute symptomatic&#xD;
                  myelitis plus inflammatory CSF analysis (e.g. elevated WBC and IgG index) or&#xD;
                  imaging consistent with inflammatory myelopathy). LETM must be diagnosed at least&#xD;
                  3 months prior to the screening visit.&#xD;
&#xD;
               -  Patient with MS defined by McDonald criteria [1] or Poser criteria [2] at least 3&#xD;
                  months prior to screening visit.&#xD;
&#xD;
               -  Patients with post-infectious, autoimmune or idiopathic TM diagnosed by a&#xD;
                  neurologist at least 6 months prior to the screening visit.&#xD;
&#xD;
          -  Patient's chronic pain must be neuropathic in nature, and anatomically plausible based&#xD;
             on underlying neuropathology. If patient has an additional source of pain (e.g.,&#xD;
             vascular ischemic pain, transient spasm associated pain, headache, chronic lower back&#xD;
             pain or concomitant osteoarthritic joint pain), the central neuropathic pain must be&#xD;
             clearly identifiable by the patient, as assessed by the Investigator.&#xD;
&#xD;
          -  The Investigator determines that the patient can enter daily NRS-11 pain intensity&#xD;
             data on an internet connected device such as a smart phone, tablet computer or desktop&#xD;
             computer with reliable internet service. Patients that do not have a device will be&#xD;
             supplied one for the duration of the study. At the direction of the patient, the&#xD;
             patient's caregivers may enter the pain intensity data.&#xD;
&#xD;
          -  At Visit 2, patient's pain is â‰¥ 4 on the NRS-11 pain intensity scale, on at least 4 of&#xD;
             the 7 days preceding randomization.&#xD;
&#xD;
          -  Patients taking immunosuppressive therapy (IST) for relapse prevention of NMOSD or TM&#xD;
             or taking disease modifying therapy (DMT) for MS must be on a stable maintenance&#xD;
             dose(s) of IST or DMT for 30 days prior to screening and must be expected to maintain&#xD;
             the IST or DMT regimenduring this study.&#xD;
&#xD;
          -  Patients taking oral corticosteroids must be on a stable dose of medication for at&#xD;
             least one week before study start and must be expected to remain on a stable dose&#xD;
             during this study. The dose may be no more than prednisolone 20 mg daily or&#xD;
             equivalent.&#xD;
&#xD;
          -  For patients taking antibody therapy for NMOSD relapse prevention (e.g. rituximab,&#xD;
             eculizumab or tocilizumab), therapy must be discontinued at least 6 months prior to&#xD;
             screening and patients must be willing to refrain from use during this study.&#xD;
&#xD;
          -  Patients taking daily neuropathic or central pain medications (e.g. gabapentin,&#xD;
             amitriptyline, lamotrigine) must be on a stable dose of medication for 30 days before&#xD;
             study start and must be expected to remain on a stable dose during this study.&#xD;
&#xD;
          -  Patients must give written informed consent.&#xD;
&#xD;
          -  Patients must be willing and able to comply with the protocol requirements for the&#xD;
             duration of the study.&#xD;
&#xD;
          -  Female patients of child-bearing potential must have a negative pregnancy test [serum&#xD;
             human chorionic gonadotropin (HCG)]. They must practice a highly effective, reliable&#xD;
             and medically approved contraceptive regimen during the study (i.e. theoretical&#xD;
             failure rate less than 1% per year including oral or parenteral hormonal&#xD;
             contraception, Nuvaring, intrauterine device (IUD) or male condom plus spermicide).&#xD;
             Post-menopausal women may enter this study. Post-menopausal women are defined as those&#xD;
             without menses in the past 12 months, and with a serum follicle stimulating hormone&#xD;
             (FSH) in the post-menopausal range. Women who are surgically sterile may enter this&#xD;
             study with historical documentation of surgical procedure and a negative pregnancy&#xD;
             test.&#xD;
&#xD;
          -  Male patients must be willing to use a condom with sexual partners during this study&#xD;
             until the poststudy visit. Male patients must be willing to abstain from sperm&#xD;
             donation for 3 months after the completion of this study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with chronic central pain due to trauma, vascular causes, active infection,&#xD;
             neoplasm, radiation, metabolic, toxic or other non-inflammatory brain disease or&#xD;
             myelopathy are excluded. Patients with trigeminal neuralgia, either as an isolated&#xD;
             condition or with MS are excluded. Patients with a history of encephalitis are&#xD;
             excluded. Patients with systemic inflammatory autoimmune disorders associated with TM&#xD;
             are excluded (e.g. sarcoidosis, systemic lupus erythematosus, Sjogren's syndrome,&#xD;
             Behcet's Syndrome, rheumatoid arthritis). TM secondary to infection of the nervous&#xD;
             system is excluded (e.g. herpes virus, Lyme disease). TM associated with HIV infection&#xD;
             is excluded.&#xD;
&#xD;
          -  Patient has an onset of an MS, LETM or TM relapse or NMOSD acute episode within 60&#xD;
             days before the study start.&#xD;
&#xD;
          -  Patients with unresolved infections, AIDS myelopathy, or degenerative neurological&#xD;
             conditions.&#xD;
&#xD;
          -  Patient has received the following within 60 days before study start:&#xD;
&#xD;
               -  Intrathecal baclofen.&#xD;
&#xD;
               -  Injection therapies such a botulinum toxin, anesthetic or nerve block to control&#xD;
                  pain.&#xD;
&#xD;
               -  Plasma exchange&#xD;
&#xD;
          -  Patients taking daily oral opioid drugs are excluded.&#xD;
&#xD;
          -  Patient is taking carbamazepine or oxcarbazine or eslicarbazepine or other potent&#xD;
             cytochrome P450 3A4/5 inducers [e.g. rifampin, St. John's Wort (Hypericum perforatum),&#xD;
             phenytoin]. Patient is taking strong P450 3A4/5 inhibitors including atazanavir,&#xD;
             bocepravir, clarithromycin, grapefruit juice, indinavir, itraconazole, ketoconazole,&#xD;
             nefazodone, nelfinavir, posaconazole, ritonavir, saquinavir, telithromycin, or&#xD;
             voriconazole.&#xD;
&#xD;
          -  Patient has evidence of alcohol, drug or chemical abuse, at study start or within 1&#xD;
             year before the study start.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jacqueline Palace, FRCP DM</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oxford University Hospitals NHS Trust</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anu Jacob, MD DM FRCP</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Walton Centre</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Walton Centre</name>
      <address>
        <city>Liverpool</city>
        <zip>L97LJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oxford University Hospitals NHS Foundation Trust</name>
      <address>
        <city>Oxford</city>
        <zip>OX3 9DU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>May 1, 2017</study_first_submitted>
  <study_first_submitted_qc>May 1, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 3, 2017</study_first_posted>
  <last_update_submitted>January 23, 2019</last_update_submitted>
  <last_update_submitted_qc>January 23, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 25, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myelitis</mesh_term>
    <mesh_term>Myelitis, Transverse</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Neuromyelitis Optica</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

